PT1718322E - Composições sinérgicas com fk-228 - Google Patents
Composições sinérgicas com fk-228 Download PDFInfo
- Publication number
- PT1718322E PT1718322E PT05719967T PT05719967T PT1718322E PT 1718322 E PT1718322 E PT 1718322E PT 05719967 T PT05719967 T PT 05719967T PT 05719967 T PT05719967 T PT 05719967T PT 1718322 E PT1718322 E PT 1718322E
- Authority
- PT
- Portugal
- Prior art keywords
- antitumor agent
- antitumor
- synergistic compositions
- agent
- dna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004050520 | 2004-02-25 | ||
US56607704P | 2004-04-29 | 2004-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1718322E true PT1718322E (pt) | 2011-09-05 |
Family
ID=34889383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT05719967T PT1718322E (pt) | 2004-02-25 | 2005-02-25 | Composições sinérgicas com fk-228 |
Country Status (11)
Country | Link |
---|---|
US (2) | US7951780B2 (pt) |
EP (1) | EP1718322B1 (pt) |
JP (1) | JP4930055B2 (pt) |
AT (1) | ATE516041T1 (pt) |
CA (1) | CA2557540A1 (pt) |
CY (1) | CY1111926T1 (pt) |
DK (1) | DK1718322T3 (pt) |
PL (1) | PL1718322T3 (pt) |
PT (1) | PT1718322E (pt) |
SI (1) | SI1718322T1 (pt) |
WO (1) | WO2005079827A2 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1426054B1 (en) * | 2001-08-21 | 2011-09-28 | Astellas Pharma Inc. | Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
EP1492596A1 (en) * | 2002-04-05 | 2005-01-05 | Fujisawa Pharmaceutical Co., Ltd. | Depsipeptide for therapy of kidney cancer |
MXPA05008904A (es) * | 2003-02-19 | 2005-10-05 | Astellas Pharma Inc | Metodo para estimar el efecto antitumoral del inhibidor de desacetilasa de histona. |
US7314862B2 (en) * | 2003-09-25 | 2008-01-01 | Astellas Pharma Inc. | Antitumor agent |
US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
AU2006311894A1 (en) * | 2005-11-04 | 2007-05-18 | Merck Sharp & Dohme Corp. | Method of treating cancers with SAHA and pemetrexed |
WO2007061939A2 (en) * | 2005-11-18 | 2007-05-31 | Gloucester Pharmaceuticals, Inc. | Metabolite derivatives of the hdac inhibitor fk228 |
EP2012801A4 (en) * | 2006-04-24 | 2009-08-05 | Gloucester Pharmaceuticals Inc | GEMCITABINE COMBINATION THERAPY |
WO2007146730A2 (en) | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
EP2073837B1 (en) * | 2006-10-06 | 2014-06-25 | Bavarian Nordic Inc. | Recombinant modified vaccinia ankara virus encoding a her-2 antigen in combination with a taxane for use in treating cancer |
JP2010514801A (ja) * | 2006-12-29 | 2010-05-06 | グラスター ファーマシューティカルズ, インコーポレイテッド | ロミデプシンの精製 |
EP2556838A1 (en) * | 2006-12-29 | 2013-02-13 | Gloucester Pharmaceuticals, Inc. | Romidepsin-based treatments for cancer |
US9156792B2 (en) * | 2008-05-09 | 2015-10-13 | University Of Maryland, Baltimore | Retinamide and uses thereof |
EP2366398A1 (en) * | 2010-03-17 | 2011-09-21 | Deutsches Krebsforschungszentrum | Cancer therapy with a parvovirus combined with an HDAC inhibitor |
CA2801891C (en) * | 2010-06-07 | 2020-10-27 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
US20120190817A2 (en) | 2010-07-12 | 2012-07-26 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
CN106860872B (zh) * | 2017-01-18 | 2019-03-22 | 上海交通大学 | 用于逆转肿瘤对铂类抗癌药多药耐药性的两亲性药-药纳米颗粒药物及其制备方法与应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8817743D0 (en) | 1988-07-26 | 1988-09-01 | Fujisawa Pharmaceutical Co | Fr901228 substance & preparation thereof |
JPH0315810A (ja) * | 1989-06-13 | 1991-01-24 | Minolta Camera Co Ltd | カメラ |
AU734476B2 (en) * | 1997-11-05 | 2001-06-14 | Baylor College Of Medicine | Sequences for targeting metastatic cells |
CA2386876A1 (en) * | 1999-11-10 | 2001-05-17 | Warner-Lambert Company | Combination chemotherapy |
DE60011678T2 (de) * | 1999-12-08 | 2005-07-14 | Xcyte Therapies, Inc., Seattle | Depsipeptide und deren analoge zur verwendung als immunosuppressiva |
DE60137932D1 (de) | 2000-07-17 | 2009-04-23 | Astellas Pharma Inc | Reduziertes fk228 und seine verwendung |
US7396665B2 (en) | 2000-09-01 | 2008-07-08 | Astellas Pharma, Inc. | Method of producing FR901228 |
EP1355566B1 (en) * | 2000-12-18 | 2012-11-28 | Board Of Regents, The University Of Texas System | Local regional chemotherapy and radiotherapy using in situ hydrogel |
US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
US6620816B2 (en) * | 2001-04-26 | 2003-09-16 | Bristol-Myers Squibb Company | Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide |
EP1426054B1 (en) | 2001-08-21 | 2011-09-28 | Astellas Pharma Inc. | Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
EE200400074A (et) * | 2001-08-31 | 2004-06-15 | Bristol-Myers Squibb Company | Koostised ning nende kasutamine proliferatiivsetehaiguste raviks |
EP1293205A1 (en) | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
EP1492596A1 (en) | 2002-04-05 | 2005-01-05 | Fujisawa Pharmaceutical Co., Ltd. | Depsipeptide for therapy of kidney cancer |
WO2003088954A1 (en) | 2002-04-15 | 2003-10-30 | Sloan-Kettering Institute For Cancer Research | Combination therapy for the treatment of cancer |
PA8578001A1 (es) * | 2002-08-07 | 2004-05-07 | Warner Lambert Co | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas |
WO2004064727A2 (en) | 2003-01-16 | 2004-08-05 | Georgetown University | Method of cancer treatment using hdac inhibitors |
MXPA05008904A (es) | 2003-02-19 | 2005-10-05 | Astellas Pharma Inc | Metodo para estimar el efecto antitumoral del inhibidor de desacetilasa de histona. |
PL2238982T3 (pl) | 2003-06-27 | 2013-03-29 | Astellas Pharma Inc | Środek do terapii mięsaka tkanek miękkich |
CA2472842C (en) | 2003-07-22 | 2012-05-29 | Honda Motor Co., Ltd. | Working machine |
US7314862B2 (en) | 2003-09-25 | 2008-01-01 | Astellas Pharma Inc. | Antitumor agent |
US20050187148A1 (en) | 2004-02-25 | 2005-08-25 | Yoshinori Naoe | Antitumor agent |
US7951780B2 (en) | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
-
2005
- 2005-02-24 US US11/064,292 patent/US7951780B2/en active Active
- 2005-02-25 AT AT05719967T patent/ATE516041T1/de active
- 2005-02-25 EP EP05719967A patent/EP1718322B1/en active Active
- 2005-02-25 CA CA002557540A patent/CA2557540A1/en not_active Abandoned
- 2005-02-25 PT PT05719967T patent/PT1718322E/pt unknown
- 2005-02-25 SI SI200531350T patent/SI1718322T1/sl unknown
- 2005-02-25 JP JP2006526473A patent/JP4930055B2/ja active Active
- 2005-02-25 WO PCT/JP2005/003689 patent/WO2005079827A2/en active Application Filing
- 2005-02-25 PL PL05719967T patent/PL1718322T3/pl unknown
- 2005-02-25 DK DK05719967.1T patent/DK1718322T3/da active
-
2011
- 2011-03-11 US US13/046,082 patent/US8822422B2/en active Active
- 2011-10-10 CY CY20111100965T patent/CY1111926T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1718322A2 (en) | 2006-11-08 |
ATE516041T1 (de) | 2011-07-15 |
US7951780B2 (en) | 2011-05-31 |
CA2557540A1 (en) | 2005-09-01 |
WO2005079827A3 (en) | 2005-12-08 |
US20110160295A1 (en) | 2011-06-30 |
JP4930055B2 (ja) | 2012-05-09 |
WO2005079827A2 (en) | 2005-09-01 |
CY1111926T1 (el) | 2015-11-04 |
PL1718322T3 (pl) | 2011-12-30 |
US8822422B2 (en) | 2014-09-02 |
EP1718322B1 (en) | 2011-07-13 |
US20050187149A1 (en) | 2005-08-25 |
DK1718322T3 (da) | 2011-08-29 |
SI1718322T1 (sl) | 2011-09-30 |
JP2007524650A (ja) | 2007-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1718322E (pt) | Composições sinérgicas com fk-228 | |
WO2005063232A8 (en) | Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity | |
MXPA06003222A (es) | Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii. | |
WO2007030409A3 (en) | In-can and dry coating antimicrobial compositions having hydroxy analogs of methionine and derivatives | |
WO2007054573A3 (en) | Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and egfr inhibitors or pyrimidine analogues | |
RS50660B (sr) | Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže | |
MY140514A (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
IL178727A0 (en) | Tetrahydropyridothiophene derivatives and pharmaceutical compositions containing the same | |
WO2006061258A3 (en) | Cytotoxic agents comprising new taxanes | |
WO2007126832A3 (en) | Pharmaceutical compositions for prevention of overdose or abuse | |
MX2008010801A (es) | Indolopiridinas como moduladores de quinesina eg5. | |
WO2007095258A3 (en) | Rhamnolipid compositions and related methods of use | |
TW200738283A (en) | Formulations of conjugated estrogens and bazedoxifene | |
NO20073026L (no) | 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav | |
PL1591514T3 (pl) | Zastosowanie dodatków do poprawy zapachu kompozycji węglowodorów oraz kompozycje węglowodorów zawierające takie dodatki | |
GB2437149B (en) | Synergistic preservative systems and their use in cosmetic compositions. | |
WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
WO2007044325A3 (en) | Apoe4 domain interaction inhibitors and methods of use thereof | |
WO2007124382A3 (en) | Inhaled imipenem | |
SI1883647T1 (sl) | Oligonukleotid in obsegajoča ga sestava za zdravljenje B celične neoplazme | |
EP2357003A4 (en) | ANTICANCER COMPOSITION COMPRISING ANTITUMOR SUBSTANCE AND AGENT AND HAVING INHIBITORY EFFECTS ON L1CAM ACTIVITY AND EXPRESSION | |
MY139425A (en) | Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol | |
WO2006128740A3 (en) | Anti-vascular methods and therapies employing lysyl oxidase inhibitors | |
WO2009047434A3 (fr) | Utilisation d'excipients en tant que conservateurs et composition pharmaceutique les comprenant | |
TW200503676A (en) | Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes |